ベータブロッカーは,重症の閉塞性心不全患者の1年死亡率の減少と関連しており,サブグループ間での利点の差異がある
Kai Wang1,2, Haitao Zhang3, Yanming Chen4
1Department of Cardiology, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Scientific reports
|September 1, 2025
まとめ
ベータ (β) 阻害剤は,重症心不全患者の死亡率を著しく低下させた. 益は様々なサブグループ,特に心拍数上昇やエジェクション分数減少を有するグループで観察されました.
科学分野:
- 心臓病科
- クリティカル ケア 医療
- 薬理学について
背景:
- 閉塞性心不全 (CHF) の重症患者のベータ (β) 阻害剤の役割は十分に確立されていません.
- この脆弱な集団における死亡率への影響については不確実性がある.
研究 の 目的:
- ベータ (β) 阻害剤の使用と重症のCHF患者の1年間の全因死亡率との関連を調査する.
- ベータ (β) 阻害剤療法から最も恩恵を受ける患者のサブグループを特定する.
主な方法:
- メディカル・インフォメーション・マート・イン・インテンス・ケア-IV (MIMIC-IV) データベース (2008年−2022年) を用いた遡及コホート研究.
- カプラン・マイヤー生存分析とコックス比例リスクモデルが死亡リスクの評価に用いられました.
- サブグループ分析では,様々な患者の特徴と臨床パラメータにおける治療効果を調査した.
主要な成果:
- ベータ (β) 阻害剤の使用は,1年間の全原因死亡率の有意な減少と関連していました (HR:0. 51,95%CI:0. 49- 0. 54).
- 非高齢者,男性,高血圧患者,糖尿病患者,セプシス患者,および機械呼吸器またはCRRTを受けている患者で,より大きな効果が観察されました.
- 心拍数上昇または左心室射出分数 (LVEF) が減少した患者は,顕著な生存優位性を示した.
結論:
- ベータ (β) 阻害剤の治療は,重症のCHF患者における全因死亡率の低下と関連しています.
- 高い心拍数または低いLVEFを持つ人々を含む特定のサブグループは,生存に実質的な利益を得ます.
- 測定されていない潜在的な混同因子のために,見込みのランダム化対照試験で確認する必要があります.
さらに関連する動画
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.6K
04:05Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
2.2K
関連する概念動画
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
970
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
970
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
597
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
597
01:28Antihypertensive Drugs: Types of β-Blockers
863
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
863